logo
Twitter
Discord
Email
logo
ProKidney Corp.

ProKidney Corp.

NASDAQ•PROK
CEO: Dr. Bruce Culleton M.D.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2021-06-30
ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Contact Information
2000 Frontis Plaza Blvd., Suite 250, Winston-Salem, NC, 27103, United States
336-999-7028
www.prokidney.com
Market Cap
$711.97M
P/E (TTM)
-4.6
40.5
Dividend Yield
--
52W High
$7.13
52W Low
$0.46
52W Range
31%
Rank62Top 82.4%
2.3
F-Score
Modified Piotroski Analysis
Based on 6-year fundamentals
Weak • 2.3 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2019-2024

Financial Dashboard

Q3 2025 Data

Revenue

$217.00K+0.00%
4-Quarter Trend

EPS

-$0.12-14.29%
4-Quarter Trend

FCF

-$31.79M+0.47%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Initial Revenue Generation Q3 2025 revenue reached $217K, compared to zero revenue in Q3 2024, marking initial leasing income recognition.
Operating Loss Narrowed Nine months operating loss improved by $12.47M to $(119.64)M, reflecting expense management efforts across operations.
Cash Flow Usage Decreased Net cash used in operations decreased by $14.58M to $(87.60)M for the nine months ended September 30, 2025.
Clinical Endpoint Confirmed FDA confirmed eGFR slope as surrogate endpoint for PROACT 1 BLA submission, targeting Q2 2027 readout.

Risk Factors

Substantial Stockholders' Deficit Total stockholders' deficit reached $(1.01)B as of September 30, 2025, indicating significant accumulated losses.
R&D Spending Increased Nine months R&D expenses rose $7.92M to $79.97M, primarily driven by ongoing Phase 3 trial activities.
Net Loss Widened Net loss available to Class A stockholders increased by $9.85M to $(49.76)M for the nine months period.
Future Development Uncertainty Successful development of rilparencel remains highly uncertain, requiring significant additional financial resources.

Outlook

PROACT 1 Data Timeline Anticipate topline eGFR slope data readout in Q2 2027 to support accelerated approval Biologics License Application.
REGEN-007 Positive Signal Group 1 showed 78% improvement in eGFR slope decline, suggesting evidence of a dose response relationship.
Corporate Structure Finalized Domestication finalized July 1, 2025, successfully changing incorporation jurisdiction to the State of Delaware.
R&D Spending Forecast Expect research and development expenses to increase significantly for the foreseeable future due to clinical stages.

Peer Comparison

Revenue (TTM)

Maravai LifeSciences Holdings, Inc.MRVI
$192.28M
-30.6%
AnaptysBio, Inc.ANAB
$169.47M
+196.4%
Xencor, Inc.XNCR
$167.36M
+64.5%

Gross Margin (Latest Quarter)

ProKidney Corp.PROK
100.0%
+0.0pp
Tango Therapeutics, Inc.TNGX
99.0%
-1.0pp
Xencor, Inc.XNCR
93.9%
+11.7pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
ANAB$1.39B-16.5-1101.2%4.1%
EYPT$1.26B-6.2-76.1%8.5%
PGEN$1.25B-2.9-5766.2%0.0%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
41.9%
Strong Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention

Research & Insights

Next earnings:Mar 16, 2026
|
EPS:-$0.16
|
Revenue:-
Reports
All Years

  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Nov 10, 2025|
    Revenue: $217.00K+0.0%
    |
    EPS: $-0.12-14.3%
    Beat

  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 12, 2025|
    Revenue: $221.00K+0.0%
    |
    EPS: $-0.13-18.8%
    Beat

  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 12, 2025|
    Revenue: $230.00K+0.0%
    |
    EPS: $-0.13-18.8%
    Beat

  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Mar 17, 2025|
    Revenue: $76.00K+0.0%
    |
    EPS: $-0.62-8.8%
    Miss

  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Nov 12, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.14-22.2%
    N/A

  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 9, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.16+14.3%
    N/A

  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 10, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.16-73.3%
    N/A

  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Mar 22, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.57+67.6%
    N/A